George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Q1
Ex-dividend date - Thursday 20 May 2021
The name of the game isn't the share price and whether it is the same or better 10 years later...
The name of the game is ...how many shares have you got.... gaining "market share" if you like
and how many have you managed to gain over the 10 years as a result of buying and selling through the inevitable ups and downs that economic cycles and changes in any company circumstances bring
Twonko at least we are at similar sp as of 10 years ago loads of permabear 100 companies cant say the same look at the banks bt cna etc etc the ftse is similar to a decade ago where the dow is x4. Blame the system not a solid GB company gla regards jack
Say it to my face Phildon you sad twat.
Papucel are you special needs or something? Me anti-vax? Me masquerading as someone else? Too many comics pal. Grow up.
Say it to my face Phildon you sad twat.
Twonka , missed opportunity, GSK are still working on it . Remember your words in 6 months from today.
well well well Phildon, I understand your frustration and if we look into the time perspective we may observe some very interesting similarities.
TR64 seems to have stopped his trolling on this board with antivax anti GSK clutter of this board; it may be that he was cautioned again by LS as in the past.
However, I spotted a paragraph in Ttonko posts which is almost a carbon copy of TR's "I was buying them for the current price a decade ago and whilst the div has been nice, I would also have expected the SP to keeppace with inflation as an absolute minimum," More than that I checked the history of his posts and the antivax theme is persistent as well.
I will keep a close eye if these 2 themes will develop into a compulsive obsessive manner and if it will be the case than TR is back from his ashes.
If there are better places then get gone good buy , close the door behind you
d I c k
Not so. Lockdown has seen people staying at home instead of going out for vaccinations, so vaccine income is reeduced.
This may pick up as GP's encourgae vaccination catch-up and as travel increases but who knows. What is more worrying is the long term stagnation of this share. I was buying them for the current price a decade ago and whilst the div has been nice, I would also have expected the SP to keeppace with inflation as an absolute minimum, which it has not done. Covid-19 was another missed opportunity for GSK. I am now looking for the reorganistion as a way to reduce my holding without taking too much of a hit. There are better places for my money. Including better drug Companies,
There is promising news but the shares do seem stuck in a trading range at the moment, and clearly if you can buy them close to £12, invariably you can then sell them for 10% more a few weeks later. GSK needs to break this cycle, which apart from anything else is undervaluing the overall group. The share price should be far higher than this, especially in a pandemic.
Hi P/C
Never thought I was such a pessimist esp as GSK is one of my biggest holdings. My ave cost is a fair bit higher, but the SP has dropped since the yr end results were published at end of January. The chart looks a little better now with the bounce off £12. Think we just need to be patient and will eventually be higher. Will be intersting to see how the split works and whther we get two different shares or are asked to buy new shares. At least we still get the 80p p.a divi for next 12 mths, as long as cashflow can support it.
Would be nice to get some positive news from Emma, as seems to ignore the impressive investments and JVs that I'm sure would lift the SP. Elliot's involvement created a decent move up for a day or two, but the SP been flat since; around 1350 mark.
I will be holding for a good while yet, with first target around £15 to sell one batch (1/3 of my shares) at a profit.
GLA - Cheers - CSDI
CSDI1962
amusing to read your rather bleak outlook under the thread title "Promising News " lol
but yes...like many companies ..it is likely that it will be 2022 before any significant return to pre pandemic figures come through ..
VIR-7831 : " Vir and GSK plan to immediately seek Emergency Use Authorization in the US and authorisations in other countries."
I wonder if India would be a place to start , given the drastic situation evolving over there
I am sure the exchange rate has been pegging back the UK SP for some time now.
Early last yr the R/E was $1.25 = £1, now it's over $1.40 = £1.
This is a major issue for UK holders, as earnings are in $, but then converted to £.
As the divi has been barely covered for some time at 80p p.a, the risk increases of a cut before end of year as already signalled. GSK has repeatedly indicated that earnings are down with Covid and we are not out of the woods yet.
The movement in exchange rate alone means that UK earnings (EPS) would be about 10% lower than LY if US earnings remained constant. Factor in an expected reduction in earnings (in US $) means a bigger drop in EPS.
No wonder the SP has performed poorly since last summer, and then we have the expense of splitting the company which is costing approx £1B over 2-3 yrs. Ummm - I wish the old GSK was still here where we could be confident of SP moving to £16 and back down to £14.
GLA - patience required - CSDI
Very true - although if they buy today they won't need to splash out :) looks like the US will open on the cheap.. But the point is well taken... however if the pound strengthens to the dollar, would that not help the US SP move up, in order to gain parity with the LSE SP? TBH I've no idea (my background is in pharma)
PharmaGiles..
Oh yeah...that is true...but..dont they have to splash out more dollars/cents to buy them now..given that the dollar is so weak ??
I guess the weakening dollar may not be all bad for US investors - 80p divi used to be 97 cents (£1 = $1.21) but now the same divi is giving $1.13
Part of the issue is the Dollar......dollar down, sterling up...not so good for Glaxo in terms of adjusted earnings
Hi Covgaz
Yes totally agree. Think I first bought these in 2007 at similar price to now. took 3 yrs to sell as fell in the 2008 crash.
divi been settled at 80p p.a for at least 6 yrs now, but facing a cut after this yr end.
Normally could buy below £14 and sell around £16, but trapped again since last summer as City not impressed.
i'm stcuk holding some as bought at 1612, 1479 and 1388 bw July and Nov last year. Did have 3 more batches but took loss on two to free up some capital and made profit on one batch recently (bought @ 1215 in Feb, sold @ 1354 on elliot day).
Good for income as you say, but without growth in the SP can be a tie on capital, and missed opportunity elsewhere.
GLA - CSDI
.
I remember selling these many years ago because they were a very boring hold. It seems the price is still where i sold them at. I thought this was supposed to be a blockbuster drugs company? It would seem not , but ok to hold for the divi , beats the banks hands down.
GSK did miss the boat, but the AZ vaccine seems to be hitting more setbacks on a weekly basis.
I had my first one in March & was bad = I'm not looking forward to the 2nd next month. As long as the board do their job & product demand doesn't fade, GSK should be an excellent long term dividend play.
GL & thanks for the reply.
The Loaf,
GSK have missed the boat as far as CV19 vaccine is concerned.
The SP has been in doldrums for some time, since I bought last July at 1612p.
We seeem to be consolidating bw 1325-1350 and forming a support, and with ex-divi date a fortnight away we might see a climb towards £14 which would be a start.
The SP will ultimately be driven by the split/restructure, and with a divi reduction coming into '22 I am not sure how the city will take to it. At least with Elliot supposedly involved (although not seen any RNS confirming =>3% stake) this should push the directors to get a grip and create proper value for us suffering PIs. Time will tell, but patience required for sure.
Cheers & GL - CSDI
I'm tempted to add more, as any good news on vaccine take up would surely move the sp upwards. There's also a near 6% yield too.
We will be awash with treatment options within months,
just like vaccine options.
Hopefully we get to the stage where a take at home antiviral in pill form will
be available- Pfizer hope to have theirs on the market by the end of year.
What a difference a year makes, eh.
Incredible achievements for science.
GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology Inc say the European Medicines Agency has started a rolling review of test results for their Covid-19 treatment sotrovimab. The review is for use in people 12 years and older. A rolling review means the EMA will evaluate the test data on sotrovimab as it becomes available. A formal marketing authorisation application will be made once there is enough supporting evidence. Sotrovimab has not yet been granted marketing authorisation anywhere in the world, though an Emergency Use Authorization application has been submitted to the US Food & Drug Administration.
Current stock price: 1,350.80 pence
Year-to-date change: up 0.7%
By Tom Waite; thomaslwaite@alliancenews.com